Elevation Oncology Reports Nomination Of EO-1022 As Its HER3 ADC Development Candidate
Elevation Oncology Reports Nomination Of EO-1022 As Its HER3 ADC Development Candidate
Elevation Oncology报告提名EO-1022作为其HER3 ADC开发候选药物
EO-1022 is currently progressing through preclinical development, and Elevation Oncology expects to file an investigational new drug (IND) application in 2026.
EO-1022目前正在进行临床前开发，Elevation Oncology预计将在2026年提交一份新药临床试验申请（IND）。
Elevation Oncology expects to present EO-1022 preclinical data in 1H 2025 and to file an IND application in 2026.
Elevation Oncology预计将在2025年上半年展示EO-1022的临床前数据，并在2026年提交IND申请。
资讯热榜
更新时间